ArticleFrontiers in oncology2024

Pathological response and safety of albumin-bound paclitaxel as a neoadjuvant treatment for HER2-positive breast cancer compared to docetaxel combined with anti-HER2 therapy: a real-world study.

Zhidong Lyu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.